Skip to main content

Increases in hypertension-induced cerebral microhemorrhages exacerbate gait dysfunction in a mouse model of Alzheimer’s disease

GeroScience volume 42, pages 1685–1698 (2020)Cite this article

Abstract

Clinical studies show that cerebral amyloid angiopathy (CAA) associated with Alzheimer’s disease (AD) and arterial hypertension are independent risk factors for cerebral microhemorrhages (CMHs). To test the hypothesis that amyloid pathology and hypertension interact to promote the development of CMHs, we induced hypertension in the Tg2576 mouse model of AD and respective controls by treatment with angiotensin II (Ang II) and the NO synthesis inhibitor L-NAME. The number, size, localization, and neurological consequences (gait alterations) of CMHs were compared. We found that compared to control mice, in TG2576 mice, the same level of hypertension led to significantly increased CMH burden and exacerbation of CMH-related gait alterations. In hypertensive TG2576 mice, CMHs were predominantly located in the cerebral cortex at the cortical-subcortical boundary, mimicking the clinical picture seen in patients with CAA. Collectively, amyloid pathologies exacerbate the effects of hypertension, promoting the genesis of CMHs, which likely contribute to their deleterious effects on cognitive function. Therapeutic strategies for prevention of CMHs that reduce blood pressure and preserve microvascular integrity are expected to exert neuroprotective effects in high-risk elderly AD patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672–713.

    PubMed  PubMed Central  Google Scholar 

  2. Iadecola C, Gottesman RF. Cerebrovascular alterations in Alzheimer disease. Circ Res. 2018;123:406–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Iadecola C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertension. Stroke. 2009;40:S40–4.

    PubMed  Google Scholar 

  4. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18:419–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Tarantini S, Tran CHT, Gordon GR, Ungvari Z, Csiszar A. Impaired neurovascular coupling in aging and Alzheimer's disease: contribution of astrocyte dysfunction and endothelial impairment to cognitive decline. Exp Gerontol. 2017;94:52–8.

    CAS  PubMed  Google Scholar 

  7. Toth P, Tarantini S, Csiszar A, Ungvari Z. Functional vascular contributions to cognitive impairment and dementia: mechanisms and consequences of cerebral autoregulatory dysfunction, endothelial impairment, and neurovascular uncoupling in aging. Am J Physiol Heart Circ Physiol. 2017;312:H1–H20.

    PubMed  Google Scholar 

  8. Van Skike CE, Jahrling JB, Olson AB, Sayre NL, Hussong SA, Ungvari Z, et al. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment. Am J Physiol Heart Circ Physiol. 2018;314:H693–703.

    PubMed  Google Scholar 

  9. Ungvari Z, Tarantini S, Kirkpatrick AC, Csiszar A, Prodan CI. Cerebral microhemorrhages: mechanisms, consequences, and prevention. Am J Physiol Heart Circ Physiol. 2017;312:H1128–43.

    PubMed  PubMed Central  Google Scholar 

  10. Yates PA, Sirisriro R, Villemagne VL, Farquharson S, Masters CL, Rowe CC. Cerebral microhemorrhage and brain beta-amyloid in aging and Alzheimer disease. Neurology. 2011;77:48–54.

    CAS  PubMed  Google Scholar 

  11. Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, St George-Hyslop P, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol. 2008;65:790–5.

    PubMed  Google Scholar 

  12. Yates PA, Desmond PM, Phal PM, Steward C, Szoeke C, Salvado O, et al. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology. 2014;82:1266–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Benedictus MR, Goos JD, Binnewijzend MA, Muller M, Barkhof F, Scheltens P, et al. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer’s disease. Neurobiol Aging. 2013;34:2488–94.

    CAS  PubMed  Google Scholar 

  14. Goos JD, Kester MI, Barkhof F, Klein M, Blankenstein MA, Scheltens P, et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke. 2009;40:3455–60.

    PubMed  Google Scholar 

  15. Akoudad S, Wolters FJ, Viswanathan A, de Bruijn RF, van der Lugt A, Hofman A, et al. Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurol. 2016;73:934–43.

    PubMed  PubMed Central  Google Scholar 

  16. Poels MM, Ikram MA, van der Lugt A, Hofman A, Niessen WJ, Krestin GP, et al. Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study. Neurology. 2012;78:326–33.

    CAS  PubMed  Google Scholar 

  17. Han BH, Zhou ML, Johnson AW, Singh I, Liao F, Vellimana AK, et al. Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. Proc Natl Acad Sci U S A. 2015;112:E881–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Hur J, Mateo V, Amalric N, Babiak M, Bereziat G, Kanony-Truc C, et al. Cerebrovascular beta-amyloid deposition and associated microhemorrhages in a Tg2576 Alzheimer mouse model are reduced with a DHA-enriched diet. FASEB J. 2018;32:4972–83.

    CAS  PubMed  Google Scholar 

  19. Fisher M, Vasilevko V, Passos GF, Ventura C, Quiring D, Cribbs DH. Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy. Stroke. 2011;42:3300–3.

    PubMed  PubMed Central  Google Scholar 

  20. Choi P, Ren M, Phan TG, Callisaya M, Ly JV, Beare R, et al. Silent infarcts and cerebral microbleeds modify the associations of white matter lesions with gait and postural stability: population-based study. Stroke. 2012;43:1505–10.

    PubMed  Google Scholar 

  21. de Laat KF, van den Berg HA, van Norden AG, Gons RA, Olde Rikkert MG, de Leeuw FE. Microbleeds are independently related to gait disturbances in elderly individuals with cerebral small vessel disease. Stroke. 2011;42:494–7.

    PubMed  Google Scholar 

  22. Toth P, Tarantini S, Springo Z, Tucsek Z, Gautam T, Giles CB, et al. Aging exacerbates hypertension-induced cerebral microhemorrhages in mice: role of resveratrol treatment in vasoprotection. Aging Cell. 2015;14:400–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Poels MM, Ikram MA, van der Lugt A, Hofman A, Krestin GP, Breteler MM, et al. Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study. Stroke. 2011;42:656–61.

    PubMed  Google Scholar 

  24. Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y. Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke. 2002;33:1536–40.

    PubMed  Google Scholar 

  25. Tarantini S, Valcarcel-Ares NM, Yabluchanskiy A, Springo Z, Fulop GA, Ashpole N, et al. Insulin-like growth factor 1 deficiency exacerbates hypertension-induced cerebral microhemorrhages in mice, mimicking the aging phenotype. Aging Cell. 2017;16:469–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Barthold D, Joyce G, Wharton W, Kehoe P, Zissimopoulos J. The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity. PLoS One. 2018;13:e0206705.

    PubMed  PubMed Central  Google Scholar 

  27. Faraco G, Park L, Zhou P, Luo W, Paul SM, Anrather J, et al. Hypertension enhances Abeta-induced neurovascular dysfunction, promotes beta-secretase activity, and leads to amyloidogenic processing of APP. J Cereb Blood Flow Metab. 2016;36:241–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Farkas E, De Jong GI, Apro E, De Vos RA, Steur EN, Luiten PG. Similar ultrastructural breakdown of cerebrocortical capillaries in Alzheimer's disease, Parkinson’s disease, and experimental hypertension. What is the functional link? Ann N Y Acad Sci. 2000;903:72–82.

    CAS  PubMed  Google Scholar 

  29. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology. 2009;72:1720–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Iadecola C. Hypertension and dementia. Hypertension. 2014;64:3–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, et al. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016;68:e67–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Israeli-Korn SD, Masarwa M, Schechtman E, Abuful A, Strugatsky R, Avni S, et al. Hypertension increases the probability of Alzheimer's disease and of mild cognitive impairment in an Arab community in northern Israel. Neuroepidemiology. 2010;34:99–105.

    CAS  PubMed  Google Scholar 

  33. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49–55.

    CAS  PubMed  Google Scholar 

  34. Wiesmann M, Roelofs M, van der Lugt R, Heerschap A, Kiliaan AJ, Claassen JA. Angiotensin II, hypertension, and angiotensin II receptor antagonism: roles in the behavioural and brain pathology of a mouse model of Alzheimer's disease. J Cereb Blood Flow Metab. 2017;37(7):2396–2413. https://doi.org/10.1177/0271678X16667364. 

  35. Javanshiri K, Waldo ML, Friberg N, Sjovall F, Wickerstrom K, Haglund M, et al. Atherosclerosis, hypertension, and diabetes in Alzheimer’s disease, vascular dementia, and mixed dementia: prevalence and presentation. J Alzheimers Dis. 2018;65:1247–58.

    PubMed  Google Scholar 

  36. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347–51.

    CAS  PubMed  Google Scholar 

  37. Guo Z, Qiu C, Viitanen M, Fastbom J, Winblad B, Fratiglioni L. Blood pressure and dementia in persons 75+ years old: 3-year follow-up results from the Kungsholmen Project. J Alzheimers Dis. 2001;3:585–91.

    PubMed  Google Scholar 

  38. Marr RA, Hafez DM. Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance. Front Aging Neurosci. 2014;6:187.

    PubMed  PubMed Central  Google Scholar 

  39. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging study. Neurobiol Aging. 2000;21:57–62.

    CAS  PubMed  Google Scholar 

  40. van Dijk EJ, Breteler MM, Schmidt R, Berger K, Nilsson LG, Oudkerk M, et al. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension. 2004;44:625–30.

    PubMed  Google Scholar 

  41. Joas E, Backman K, Gustafson D, Ostling S, Waern M, Guo X, et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension. 2012;59:796–801.

    CAS  PubMed  Google Scholar 

  42. Cifuentes D, Poittevin M, Bonnin P, Ngkelo A, Kubis N, Merkulova-Rainon T, et al. Inactivation of nitric oxide synthesis exacerbates the development of Alzheimer disease pathology in APPPS1 mice (amyloid precursor protein/presenilin-1). Hypertension. 2017;70:613–23.

    CAS  PubMed  Google Scholar 

  43. Cifuentes D, Poittevin M, Dere E, Broqueres-You D, Bonnin P, Benessiano J, et al. Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease. Hypertension. 2015;65:218–24.

    CAS  PubMed  Google Scholar 

  44. Capone C, Faraco G, Peterson JR, Coleman C, Anrather J, Milner TA, et al. Central cardiovascular circuits contribute to the neurovascular dysfunction in angiotensin II hypertension. J Neurosci. 2012;32:4878–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals. Arterioscler Thromb Vasc Biol. 2006;26:826–32.

    CAS  PubMed  Google Scholar 

  46. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res. 2004;95:1019–26.

    CAS  PubMed  Google Scholar 

  47. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol. 2002;283:H315–23.

    CAS  Google Scholar 

  48. Carnevale D, Lembo G. ‘Alzheimer-like’ pathology in a murine model of arterial hypertension. Biochem Soc Trans. 2011;39:939–44.

    CAS  PubMed  Google Scholar 

  49. Carnevale D, Mascio G, Ajmone-Cat MA, D'Andrea I, Cifelli G, Madonna M, et al. Role of neuroinflammation in hypertension-induced brain amyloid pathology. Neurobiol Aging. 2012;33:205 e19–29.

    Google Scholar 

  50. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, et al. Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension. 2012;60:188–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Diaz-Ruiz C, Wang J, Ksiezak-Reding H, Ho L, Qian X, Humala N, et al. Role of hypertension in aggravating Abeta neuropathology of AD type and tau-mediated motor impairment. Cardiovasc Psychiatry Neurol. 2009;2009:107286.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Hsu CY, Huang CC, Chan WL, Huang PH, Chiang CH, Chen TJ, et al. Angiotensin-receptor blockers and risk of Alzheimer’s disease in hypertension population. Circ J. 2013;77:405–10.

    PubMed  Google Scholar 

  53. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC 3rd. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci. 1995;131:162–9.

    CAS  PubMed  Google Scholar 

  54. Wakisaka Y, Chu Y, Miller JD, Rosenberg GA, Heistad DD. Critical role for copper/zinc-superoxide dismutase in preventing spontaneous intracerebral hemorrhage during acute and chronic hypertension in mice. Stroke. 2010;41(4):790-7. https://doi.org/10.1161/STROKEAHA.109.569616.

  55. Wakisaka Y, Chu Y, Miller JD, Rosenberg GA, Heistad DD. Spontaneous intracerebral hemorrhage during acute and chronic hypertension in mice. J Cereb Blood Flow Metab. 2010;30:56–69.

    CAS  PubMed  Google Scholar 

  56. Wakisaka Y, Miller JD, Chu Y, Baumbach GL, Wilson S, Faraci FM, et al. Oxidative stress through activation of NAD(P)H oxidase in hypertensive mice with spontaneous intracranial hemorrhage. J Cereb Blood Flow Metab. 2008;28:1175–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Tarantini S, Giles CB, Wren JD, Ashpole NM, Valcarcel-Ares MN, Wei JY, et al. IGF-1 deficiency in a critical period early in life influences the vascular aging phenotype in mice by altering miRNA-mediated post-transcriptional gene regulation: implications for the developmental origins of health and disease hypothesis. Age (Dordr). 2016;38:239–58.

    CAS  Google Scholar 

  58. Tarantini S, Yabluchanskiy A, Fulop GA, Kiss T, Perz A, O'Connor D, et al. Age-related alterations in gait function in freely moving male C57BL/6 mice: translational relevance of decreased cadence and increased gait variability. J Gerontol A Biol Sci Med Sci. 2018.

  59. Blazkiewicz M, Wiszomirska I, Wit A. Comparison of four methods of calculating the symmetry of spatial-temporal parameters of gait. Acta Bioeng Biomech. 2014;16:29–35.

    PubMed  Google Scholar 

  60. Tarantini S, Yabluchanskiy A, Fulop GA, Kiss T, Perz A, O'Connor D, et al. Age-related alterations in gait function in freely moving male C57BL/6 mice: translational relevance of decreased cadence and increased gait variability. J Gerontol A Biol Sci Med Sci. 2019;74:1417–21.

    PubMed  Google Scholar 

  61. Passos GF, Kilday K, Gillen DL, Cribbs DH, Vasilevko V. Experimental hypertension increases spontaneous intracerebral hemorrhages in a mouse model of cerebral amyloidosis. J Cereb Blood Flow Metab. 2016;36:399–404.

    CAS  PubMed  Google Scholar 

  62. Toth P, Tucsek Z, Sosnowska D, Gautam T, Mitschelen M, Tarantini S, et al. Age-related autoregulatory dysfunction and cerebromicrovascular injury in mice with angiotensin II-induced hypertension. J Cereb Blood Flow Metab. 2013;33:1732–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Nakamura T, Meguro K, Sasaki H. Relationship between falls and stride length variability in senile dementia of the Alzheimer type. Gerontology. 1996;42:108–13.

    CAS  PubMed  Google Scholar 

  64. Montero-Odasso M, Oteng-Amoako A, Speechley M, Gopaul K, Beauchet O, Annweiler C, et al. The motor signature of mild cognitive impairment: results from the gait and brain study. J Gerontol A Biol Sci Med Sci. 2014;69:1415–21.

    PubMed  PubMed Central  Google Scholar 

  65. Rosso AL, Olson Hunt MJ, Yang M, Brach JS, Harris TB, Newman AB, et al. Higher step length variability indicates lower gray matter integrity of selected regions in older adults. Gait Posture. 2014;40:225–30.

    PubMed  PubMed Central  Google Scholar 

  66. Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait speed and survival in older adults. JAMA. 2011;305:50–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Verghese J, Holtzer R, Lipton RB, Wang C. Quantitative gait markers and incident fall risk in older adults. J Gerontol A Biol Sci Med Sci. 2009;64:896–901.

    PubMed  Google Scholar 

  68. Verghese J, Robbins M, Holtzer R, Zimmerman M, Wang C, Xue X, et al. Gait dysfunction in mild cognitive impairment syndromes. J Am Geriatr Soc. 2008;56:1244–51.

    PubMed  PubMed Central  Google Scholar 

  69. Verghese J, Wang C, Lipton RB, Holtzer R, Xue X. Quantitative gait dysfunction and risk of cognitive decline and dementia. J Neurol Neurosurg Psychiatry. 2007;78:929–35.

    PubMed  PubMed Central  Google Scholar 

  70. Verlinden VJ, van der Geest JN, Hoogendam YY, Hofman A, Breteler MM, Ikram MA. Gait patterns in a community-dwelling population aged 50 years and older. Gait Posture. 2013;37:500–5.

    CAS  PubMed  Google Scholar 

  71. Visser H. Gait and balance in senile dementia of Alzheimer’s type. Age Ageing. 1983;12:296–301.

    CAS  PubMed  Google Scholar 

  72. Wittwer JE, Webster KE, Hill K. Reproducibility of gait variability measures in people with Alzheimer’s disease. Gait Posture. 2013;38:507–10.

    PubMed  Google Scholar 

  73. Manso Y, Comes G, Lopez-Ramos JC, Belfiore M, Molinero A, Giralt M, et al. Overexpression of metallothionein-1 modulates the phenotype of the Tg2576 mouse model of Alzheimer’s disease. J Alzheimers Dis. 2016;51:81–95.

    CAS  PubMed  Google Scholar 

  74. Arima H, Tzourio C, Anderson C, Woodward M, Bousser MG, MacMahon S, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke. 2010;41:394–6.

    CAS  PubMed  Google Scholar 

  75. Schrag M, McAuley G, Pomakian J, Jiffry A, Tung S, Mueller C, et al. Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol. 2010;119:291–302.

    PubMed  PubMed Central  Google Scholar 

  76. Ni J, Auriel E, Martinez-Ramirez S, Keil B, Reed AK, Fotiadis P, et al. Cortical localization of microbleeds in cerebral amyloid angiopathy: an ultra high-field 7T MRI study. J Alzheimers Dis. 2015;43:1325–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke. 1983;14:924–8.

    CAS  PubMed  Google Scholar 

  78. Ding J, Sigurethsson S, Jonsson PV, Eiriksdottir G, Meirelles O, Kjartansson O, et al. Space and location of cerebral microbleeds, cognitive decline, and dementia in the community. Neurology. 2017;88:2089–97.

    PubMed  PubMed Central  Google Scholar 

  79. Michael N, Grigoryan MM, Kilday K, Sumbria RK, Vasilevko V, van Ryn J, et al. Effects of dabigatran in mouse models of aging and cerebral amyloid angiopathy. Front Neurol. 2019;10:966.

    PubMed  PubMed Central  Google Scholar 

  80. Lee JM, Yin K, Hsin I, Chen S, Fryer JD, Holtzman DM, et al. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J Neurol Sci. 2005;229–230:249–54.

    PubMed  Google Scholar 

  81. Lee JM, Yin KJ, Hsin I, Chen S, Fryer JD, Holtzman DM, et al. Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol. 2003;54:379–82.

    CAS  PubMed  Google Scholar 

  82. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, et al. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci. 2005;25:1769–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 2018;14:450–64.

    CAS  PubMed  Google Scholar 

  84. Sen A, Nelson TJ, Alkon DL, Hongpaisan J. Loss in PKC epsilon causes downregulation of MnSOD and BDNF expression in neurons of Alzheimer’s disease Hippocampus. J Alzheimers Dis. 2018;63:1173–89.

    CAS  PubMed  Google Scholar 

  85. Springo Z, Tarantini S, Toth P, Tucsek Z, Koller A, Sonntag WE, et al. Aging exacerbates pressure-induced mitochondrial oxidative stress in mouse cerebral arteries. J Gerontol A Biol Sci Med Sci. 2015;70:1355–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Dushpanova A, Agostini S, Ciofini E, Cabiati M, Casieri V, Matteucci M, et al. Gene silencing of endothelial von Willebrand factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells. Sci Rep. 2016;6:30048.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Yan P, Zhu A, Liao F, Xiao Q, Kraft A, Gonzales E, et al. Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy. Stroke. 2015;46:1633–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Park L, Uekawa K, Garcia-Bonilla L, Koizumi K, Murphy M, Pistik R, et al. Brain perivascular macrophages initiate the neurovascular dysfunction of Alzheimer Abeta peptides. Circ Res. 2017;121:258–69.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Lee SH, Lee ST, Kim BJ, Park HK, Kim CK, Jung KH, et al. Dynamic temporal change of cerebral microbleeds: long-term follow-up MRI study. PLoS One. 2011;6:e25930.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Seo SW, Hwa Lee B, Kim EJ, Chin J, Sun Cho Y, Yoon U, et al. Clinical significance of microbleeds in subcortical vascular dementia. Stroke. 2007;38:1949–51.

    PubMed  Google Scholar 

  91. Bature F, Guinn BA, Pang D, Pappas Y. Signs and symptoms preceding the diagnosis of Alzheimer’s disease: a systematic scoping review of literature from 1937 to 2016. BMJ Open. 2017;7:e015746.

    PubMed  PubMed Central  Google Scholar 

  92. Rucco R, Agosti V, Jacini F, Sorrentino P, Varriale P, De Stefano M, et al. Spatio-temporal and kinematic gait analysis in patients with frontotemporal dementia and Alzheimer’s disease through 3D motion capture. Gait Posture. 2017;52:312–7.

    PubMed  Google Scholar 

  93. Allan LM, Ballard CG, Burn DJ, Kenny RA. Prevalence and severity of gait disorders in Alzheimer’s and non-Alzheimer's dementias. J Am Geriatr Soc. 2005;53:1681–7.

    PubMed  Google Scholar 

  94. Tarantini S, Tucsek Z, Valcarcel-Ares M, Toth P, Gautam T, Giles C, et al. Circulating IGF-1 deficiency exacerbates hypertension-induced microvascular rarefaction in the mouse hippocampus and retrosplenial cortex: implications for cerebromicrovascular and brain aging. Age (Dordr). 2016;38:273–89.

    CAS  Google Scholar 

  95. Iadecola C, Gottesman RF. Neurovascular and cognitive dysfunction in hypertension. Circ Res. 2019;124:1025–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Kazama K, Wang G, Frys K, Anrather J, Iadecola C. Angiotensin II attenuates functional hyperemia in the mouse somatosensory cortex. Am J Physiol Heart Circ Physiol. 2003;285:H1890–9.

    CAS  PubMed  Google Scholar 

  97. Lin AL, Zheng W, Halloran JJ, Burbank RR, Hussong SA, Hart MJ, et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. J Cereb Blood Flow Metab. 2013;33:1412–21.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by grants from the American Heart Association (ST), the Oklahoma Center for the Advancement of Science and Technology (to AC, AY, ZU), the National Institute on Aging (R01-AG047879; R01-AG038747; R01-AG055395), the National Institute of Neurological Disorders and Stroke (NINDS; R01-NS056218 to AC, R01-NS100782 to ZU), the National Institute of General Medical Sciences Oklahoma Shared Clinical and Translational Resources (OSCTR) (GM104938, to AY), the Presbyterian Health Foundation (to ZU, AC, AY), the NIA-supported Geroscience Training Program in Oklahoma (T32AG052363), the Oklahoma Nathan Shock Center (P30AG050911), and the Cellular and Molecular GeroScience CoBRE (1P20GM125528, sub#5337). The funding sources had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Author information

Author notes

  1. Ádám Nyúl-Tóth, Stefano Tarantini and Andriy Yabluchanskiy contributed equally to this work.

Affiliations

  1. Vascular Cognitive Impairment and Neurodegeneration Program, Reynolds Oklahoma Center on Aging/Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

    Ádám Nyúl-Tóth, Stefano Tarantini, Tamas Kiss, Peter Toth, Amber Tarantini, Andriy Yabluchanskiy, Anna Csiszar & Zoltan Ungvari

  2. International Training Program in Geroscience, Institute of Biophysics, Biological Research Centre, Szeged, Hungary

    Ádám Nyúl-Tóth

  3. International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Department of Public Health, Semmelweis University, Budapest, Hungary

    Stefano Tarantini, Peter Toth, Amber Tarantini & Zoltan Ungvari

  4. International Training Program in Geroscience, Theoretical Medicine Doctoral School/Departments of Medical Physics and Informatics & Cell Biology and Molecular Medicine, University of Szeged, Szeged, Hungary

    Tamas Kiss, Anna Csiszar & Zoltan Ungvari

  5. International Training Program in Geroscience, Doctoral School of Clinical Medicine, Department of Neurosurgery and Szentagothai Research Center, Medical School, University of Pecs, Pecs, Hungary

    Peter Toth

  6. Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Veronica Galvan

  7. Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Veronica Galvan

  8. South Texas Veterans Health Care System, San Antonio, TX, USA

    Veronica Galvan

  9. Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Veronica Galvan

  10. Department of Biochemistry and Molecular Biology, Reynolds Oklahoma Center on Aging/Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA

    Zoltan Ungvari

Authors
  1. Ádám Nyúl-Tóth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Tarantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tamas Kiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Toth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Veronica Galvan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amber Tarantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andriy Yabluchanskiy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anna Csiszar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zoltan Ungvari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zoltan Ungvari.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nyúl-Tóth, Á., Tarantini, S., Kiss, T. et al. Increases in hypertension-induced cerebral microhemorrhages exacerbate gait dysfunction in a mouse model of Alzheimer’s disease. GeroScience 42, 1685–1698 (2020). https://doi.org/10.1007/s11357-020-00256-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11357-020-00256-3

Keywords

  • Dementia
  • Microbleed
  • Arteriole
  • Gait dysfunction
  • Cerebral amyloid angiopathy